Quantcast

Latest Bite Stories

3101dddf17ce9252e3bf135a455b97a11
2009-06-22 12:50:00

Researchers are now warning that doctors should be aware of the risk of MRSA infection when treating people for dog and cat bites. MRSA (multidrug-resistant Staphylococcus aureus) is a bacterium responsible for difficult-to-treat infections in humans. The bacteria are found on everyone's skin and are usually harmless, but an insect bite or a skin wound of any kind can allow the bacteria to creep in and cause an infection. Lancet Infectious Diseases reviewed existing evidence on infection...

2009-06-18 06:00:00

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed. The double-blind, randomized, placebo controlled study will investigate the safety and...

2009-06-08 06:00:00

Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma (NHL) at the 14th Congress of the...

2009-06-08 06:00:00

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R)...

2009-06-02 06:00:00

BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blinatumomab data presented on June 5th and 6th at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at www.micromet-inc.com. Forum:...

2009-06-01 06:00:00

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic...

2009-05-20 06:00:00

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster...

ac5a1edd09a20aeeb091285da1d82a0a1
2009-05-19 13:44:50

Australian researchers have discovered what makes the Komodo dragon's bite so deadly for its prey. Scientists previously considered that the world's largest lizard's mouth held deadly bacteria that stopped its victims' blood from clotting. Walter Auffenberg put that theory forward in 1981. But lead researcher Bryan Fry used magnetic resonance imagery to show that the deadly lizard packs a venomous bite, as seen through its venom gland with ducts that lead to their teeth. Fry used 3-D computer...

2009-05-06 06:00:00

BETHESDA, Md., May 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2009. In the first quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones include the execution...

2009-04-30 06:00:00

BETHESDA, Md., April 30 /PRNewswire/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Wednesday, May 6, 2009, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its financial results for the first quarter of 2009. Micromet anticipates releasing its financial results at 7:00 am...


Latest Bite Reference Libraries

0_e288c9a7e7e932afbeba3516c20e64f2
2009-06-16 22:38:30

The Brown Recluse Spider (Loxosceles reclusa) is a species of arachnid that is native to the USA from the southern Midwest south to the Gulf of Mexico. It can be found in Canada as well around southeast Ontario, and southern Quebec. Its range lies from southeastern Nebraska through southern Iowa, Illinois, and Indiana to southwestern Ohio. In the south, it is native from central Texas to western Georgia. It is not usually found west of the Rocky Mountains. Contrary to popular belief, this...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related